Hepatocyte

LifeNet Health LifeSciences launches TruVivo™, a pioneering all-human 2D+ hepatic system, to revolutionize compound discovery

Retrieved on: 
Tuesday, April 4, 2023
Tissue, Drug development, Bile, 3D, Toxicology, Research, Cell, Society of Toxicology, Biomarker, Doctor of Philosophy, Hepatocyte, 2D, Movement, Liver, Longevity, B cell, Phenotype, Vaccine, 3D printing, Fine chemical

Their findings have been featured in multiple scientific poster presentations , including most recently at the 2023 Society of Toxicology annual meeting.

Key Points: 
  • Their findings have been featured in multiple scientific poster presentations , including most recently at the 2023 Society of Toxicology annual meeting.
  • "TruVivo delivers a superior combination of human relevance, reliability, simplicity, and longevity," said Louis Dias, General Manager of LifeNet Health LifeSciences.
  • "This technological breakthrough reflects LifeNet Health's continued commitment to accelerating discovery in the field of life sciences," said LifeNet Health President and CEO Rony Thomas.
  • "TruVivo will expedite drug development efforts, supporting lifesaving pharmaceuticals, treatments and cures – bringing a new platform to researchers around the world."

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023
Gene editing, BCMA, Research and development, IND World's Fair Line, Stem cell, Development, Culture, Cancer, Bangladesh Technical Education Board, CD47, Epithelium, ADA, Hepatocyte, State Administrative Expenses, CAR, ISSCR, CD19, Cell, Success, Immune system, Diabetes, Research, CD22, AACR, Lymphoid leukemia, NIH, Patient, ASH, Safety, Letter, Contingency, Retinal pigment epithelium, Serum, Survival, SANA, Autoimmunity, Administration, Immunosuppression, Fusome, Investment, GAAP, Disease, Biotechnology, IND, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Beam

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 9, 2023
Oncology, Health, Infectious Diseases, Genetics, General Health, Clinical Trials, Biotechnology, ASCO, NHP, Cell, OTC, Novartis, Research, Patient, Gene editing, Agriculture, HBV, Hepatocyte, Information technology, Trial of the century, Development, Cash, IND, Hemoglobinopathy, Precision BioSciences, Lilly, Non-Hodgkin lymphoma, HBsAg, DMD, Duchenne muscular dystrophy, State Administrative Expenses, Molecular Partners, Cyclophosphamide, ASH, Insurance, CTA, NHL, Tissue, University, FDA, R, Precision, Drug discovery, CMC, Administration, Infant, CAR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PCSK9, Food, Vivo, Sickle cell disease, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a business update.
  • Responses from the FDA on analytical methods, proposed potency assays, and manufacturing processes are further guiding clinical development.
  • The Company also plans to complete Phase 1 dose escalation for PBCAR19B in the earlier line NHL setting.
  • Fiscal Year 2022 Financial Results:
    Cash and Cash Equivalents: As of December 31, 2022, Precision had $189.6 million in cash and cash equivalents.

Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, February 23, 2023
Tissue, DNA, Immune system, Research, Engineering, G&A, Hepatocyte, Haemophilia, R, Liver, Hepatology, Therapy, LNP, D, Spleen, Vaccine, Cryptocurrency

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2023 and reported fourth quarter and full year 2022 financial results.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co .
  • (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2023 and reported fourth quarter and full year 2022 financial results.
  • “Generation Bio is aiming to be the new modality leader for non-viral DNA therapeutics.
  • This type of ctLNP could extend the reach of nucleic acid therapeutics to new tissues and cell types beyond the liver.

Dr. Lilly Xu Named President of Shanghai ChemPartner

Retrieved on: 
Thursday, February 23, 2023
Pleasure, CDMO, Pharmacology, Amgen, Drug discovery, GM, Hepatocyte, Biology, Saint Louis University, CCO, Growth, Doctor of Philosophy, DMPK, Sanofi, Fine chemical

SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner.

Key Points: 
  • SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner.
  • She joined ChemPartner in 2017 to lead the strategic drug discovery services as Senior Vice President and Head of DMPK and Exploratory Toxicology.
  • Prior to joining ChemPartner, Dr. Xu held various positions in US biotech and pharmaceutical companies including Amgen and Sanofi US.
  • Livia Legg, CCO at Shanghai ChemPartner and GM of ChemPartner Corporation (US) and ChemPartner Europe added, "I have had the pleasure of working with Dr. Xu over the past six years at ChemPartner.

Dr. Lilly Xu Named President of Shanghai ChemPartner

Retrieved on: 
Thursday, February 23, 2023
Pleasure, CDMO, Pharmacology, Amgen, Drug discovery, GM, Hepatocyte, Biology, Saint Louis University, CCO, Growth, Doctor of Philosophy, DMPK, Sanofi, Fine chemical

SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner.

Key Points: 
  • SHANGHAI, Feb. 23, 2023 /PRNewswire/ -- ChemPartner announced today the appointment of Lilly Xu, Ph.D. as President of Shanghai ChemPartner.
  • She joined ChemPartner in 2017 to lead the strategic drug discovery services as Senior Vice President and Head of DMPK and Exploratory Toxicology.
  • Prior to joining ChemPartner, Dr. Xu held various positions in US biotech and pharmaceutical companies including Amgen and Sanofi US.
  • Livia Legg, CCO at Shanghai ChemPartner and GM of ChemPartner Corporation (US) and ChemPartner Europe added, "I have had the pleasure of working with Dr. Xu over the past six years at ChemPartner.

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023: Sector to Reach $4.36 Billion by 2027 at a 10.1% CAGR - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 21, 2023
Health, Stem Cells, Benchmark, Tissue, B cell, Diabetes, Create, Agriculture, National Institutes of Health, Therapy, Coronavirus, Cell, Cancer, Intramural sports, Cell potency, IPSC, Partnership, Multiple myeloma, Acquisition, Risk, Fibroblast, Hepatocyte, NIH Intramural Research Program, Conditional sentence, Stem cell, Patient, Death, United States Department of Health and Human Services, Child, Growth, IRB, NIH, Neoplasm, IRP, Human services, Century, Stroke, Institutional review board, Catalent, Bristol Myers Squibb, Prevalence, Checklist, Acute myeloid leukemia, Vaccine, Pharmaceutical industry, Induce, Keratinocyte

The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Induced Pluripotent Stem Cell (iPSC) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the induced pluripotent stem cell (iPSC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • An increase in the prevalence of chronic disorders is one of the major factors that is driving the growth of the Induced pluripotent stem cell market.
  • The potential risk of tumour is one of the major restraints on the growth of the Induced pluripotent stem cell market.

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

Retrieved on: 
Thursday, February 16, 2023
Well, MBA, NASH, Toxicity, DNA, Viral, Hepatitis, PD, Therapy, Taipei International Convention Center, Treatment, PD-1, PD-L1, Thyroid, Safety, Toxicology, Hyperlipidemia, Patient, Small RNA, RNA, Fatty liver disease, HV, Doctor of Philosophy, Hepatocyte, HBV, Hepatitis B, Tolerability, Thyroid hormones, Novel, Pharmacology, CHB, SAN, Jacob Aligo, Conference, CccDNA, Vaccine, Pharmaceutical industry, Dietary supplement, HBsAg, Single, Pharmacokinetics, Liver

Posters will be available for viewing throughout the conference for attendees and are also available on Aligos’ corporate website’s Scientific Presentations & Conferences page.

Key Points: 
  • Posters will be available for viewing throughout the conference for attendees and are also available on Aligos’ corporate website’s Scientific Presentations & Conferences page.
  • HBsAg declines as high as 0.78 log10 IU/mL were seen in subjects achieving drug exposures corresponding to 300 mg for 28 days.
  • Additionally, subjects achieving drug exposures corresponding to 300 mg for 28 days demonstrated HBsAg declines up to 0.78 log10 IU/mL.
  • ALG-093702’s potential to mitigate immune-related systemic toxicity makes it a candidate for use in CHB or other indications in the liver.

Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders

Retrieved on: 
Thursday, February 16, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MBA, Protein, ATACS, Drug development, RA, Hepatocyte, Therapy, Raven, Asialoglycoprotein receptor, MEC, AVM, Doctor of Philosophy, Autoimmunity, MD, Vaccine, Management

Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders.

Key Points: 
  • Avilar Therapeutics , a biopharmaceutical company focused on extracellular protein degradation, today announced it has raised additional funding with an expanded syndicate of new investors to support advancing a pipeline of first-in-class extracellular protein degraders.
  • “Avilar is pioneering the next frontier in protein degradation and we are excited that our significant progress over the past year in discovering and advancing extracellular protein degraders has attracted this group of leading investors,” said Daniel Grau, CEO and President of Avilar Therapeutics.
  • In addition, the funding will be used to grow the company and expand the Avilar platform of proprietary technologies, all custom-built and tailored to designing and building extracellular protein degraders.
  • “Their expertise in company building, capital formation, and drug development will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.”
    Avilar is building a novel class of protein degraders that target disease-causing extracellular proteins, thereby extending the reach of protein degradation beyond first generation degraders that target intracellular proteins.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023
Disease, FRDA, Genome, Cystic fibrosis transmembrane conductance regulator, Swelling, CGD, Safety data sheet, Respiratory tract, GAA, Tissue, Cystic fibrosis, CD34, CMC, AAV, Heart, Failure rate, CFTR, Mitochondrion, Culture, DNA, LNP, Safety, Mutation, IPSC, Gene editing, Central nervous system, Hepatocyte, Patient, Degenerative disease, CF, Bronchiole, Neuron, PCSK9, Ataxia, Liver, Human, FXN, Inflammation, Chronic granulomatous disease, Eye, Investment, Prime editing, Vaccine, Pharmaceutical industry, Medical device, IND, WD, Frataxin

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.